Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes.
Various incubation conditions of human hepatocytes were compared for their accuracy in predicting the in vivo hepatic clearance (CL(H)) of model compounds. The test compounds were the highly cleared, low protein bound naloxone (in vivo CL(H) = 25 ml min(-1) kg(-1); free fraction = 0.6), the medium clearance, highly protein bound midazolam (CL(H) = 12 ml min(-1) kg(-1); free fraction = 0.04) and the low clearance, highly protein bound bosentan (CL(H) = 3.9 ml min(-1) kg(-1); free fraction = 0.02). Each compound was tested in three 'hepatocyte systems', using resections from three donors, in the presence and absence of human serum. Those hepatocyte systems were: conventional primary cultures, freshly isolated suspensions and cryopreserved suspended hepatocytes. Except for a twofold overestimated CL(H) for bosentan from conventional primary cultures, and despite variable cryopreservation recoveries, similar predictions of CL(H) were recorded with all hepatocyte systems. Moreover, the CL(H) values obtained with cryopreserved suspended hepatocytes were similar to those obtained with freshly isolated suspensions. For midazolam and bosentan, the predicted in vivo CL(H) was markedly higher in the presence of serum, whereas serum had little influence on the scaled-up CL(H) of naloxone. In vivo, CL(H) was properly approached for naloxone and bosentan (particularly from experiments in the presence of serum), but it was strongly underestimated for midazolam (particularly in the absence of serum). Additional compounds need to be investigated to confirm the above findings as well as to assess why the clearances of some highly protein-bound compounds are still considerably underestimated.
Blanchard
N
N
F. Hoffmann-La Roche AG, Pharmaceuticals Division, CH-4070 Basel, Switzerland.
Alexandre
E
E
Abadie
C
C
Lavé
T
T
Heyd
B
B
Mantion
G
G
Jaeck
D
D
Richert
L
L
Coassolo
P
P
D000465:Algorithms; D000077300:Bosentan; D018929:Cell Culture Techniques / Q000379:methods*; D002478:Cells, Cultured; D003198:Computer Simulation; D015925:Cryopreservation / Q000379:methods; D022781:Hepatocytes / Q000378:metabolism*; D006801:Humans; D008874:Midazolam / Q000493:pharmacokinetics*; D008954:Models, Biological; D009270:Naloxone / Q000493:pharmacokinetics*; D013449:Sulfonamides / Q000493:pharmacokinetics*
D013449:Sulfonamides; D009270:Naloxone; D000077300:Bosentan; D008874:Midazolam